American Psychiatric Association Annual Meeting

American Psychiatric Association Annual Meeting

Source:

Nemeroff CB, et al. Neurobiology and treatment of post-traumatic stress disorder. Presented at: American Psychiatric Association annual meeting; May 21-25, 2022; New Orleans.

Disclosures: Nemeroff reports receiving research grants from NIH; consulting for AbbVie, Acadia Pharmaceuticals, Alfasigma, ANeuroTech (division of Anima BV), BioXcel Therapeutics, Clexio, Corcept Therapeutics Pharmaceuticals Co., EcoR1, EMA Wellness, Engrail Therapeutics, GoodCap Pharmaceuticals, Intra-Cellular Therapies, Magstim, Navitor Pharmaceuticals, Pasithea Therapeutic Corp., Sage, Senseye, Signant Health, Silo Pharma, SK Life Science and XW Pharma; as well as being a stockholder for Antares, BI Gen Holdings, Corcept Therapeutics Pharmaceuticals Co., EMA Wellness, Naki Health, Seattle Genetics, TRUUST Neuroimaging and Xhale.
June 02, 2022
1 min watch
Save

VIDEO: ‘Future is bright’ for patients with PTSD

Source:

Nemeroff CB, et al. Neurobiology and treatment of post-traumatic stress disorder. Presented at: American Psychiatric Association annual meeting; May 21-25, 2022; New Orleans.

Disclosures: Nemeroff reports receiving research grants from NIH; consulting for AbbVie, Acadia Pharmaceuticals, Alfasigma, ANeuroTech (division of Anima BV), BioXcel Therapeutics, Clexio, Corcept Therapeutics Pharmaceuticals Co., EcoR1, EMA Wellness, Engrail Therapeutics, GoodCap Pharmaceuticals, Intra-Cellular Therapies, Magstim, Navitor Pharmaceuticals, Pasithea Therapeutic Corp., Sage, Senseye, Signant Health, Silo Pharma, SK Life Science and XW Pharma; as well as being a stockholder for Antares, BI Gen Holdings, Corcept Therapeutics Pharmaceuticals Co., EMA Wellness, Naki Health, Seattle Genetics, TRUUST Neuroimaging and Xhale.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

NEW ORLEANS – A number of new treatments are on the horizon for PTSD, making the future bright for patients with this condition, Charles B. Nemeroff, MD, PhD, said at the American Psychiatric Association annual meeting.

Ketamine, certain psychedelics and the use of neuromodulation such as transcranial magnetic stimulation are new options, Nemeroff, of the University of Texas at Austin Dell Medical School, said.